T41. SAFETY PROFILE OF ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL FOR THE POTENTIAL TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT

BACKGROUND: Many patients with schizophrenia (SCZ) do not fully respond to antipsychotic (AP) treatment despite adherence and require augmentation, often with an AP with similar mode of action. Evidence supporting polypharmacy is limited and adding another AP increases associated risks of adverse ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Bugarski-Kirola, Dragana, Nunez, Rene, Odetalla, Ramzey, Bari, Mohammed A, Bitter, Istvan, Feldman, Peter D, (Cathy) Liu, I-Yuan, Stankovic, Srdjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Session III
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234223/
http://dx.doi.org/10.1093/schbul/sbaa029.601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234223/
http://dx.doi.org/10.1093/schbul/sbaa029.601

Ejemplares similares